Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

Ledermann, Jonathan A.Zurawski, B.Raspagliesi, FrancescoDe Giorgi, U.Arranz Arija, JoséRomeo Marin, M.Lisyanskaya, A.Póka, RóbertMarkowska, J.Cebotaru, C.Casado Herraez, A.Colombo, N.Kutarska, E.Hall, M.Jacobs, A.Ahrens-Fath, I.Baumeister, H.Zurlo, A.Sehouli, Jalid2024-05-022024-05-022022ESMO Open. -7 : 1 (2022), p. 1-8. -(cikkazonosító)100311. -ESMO Open. - 2059-70292059-7029https://hdl.handle.net/2437/369529Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM120842OrvostudományokKlinikai orvostudományokhttps://linkinghub.elsevier.com/retrieve/pii/S2059702921002738szerzőhttp://dx.doi.org/10.1016/j.esmoop.2021.1003112024-05-0200081987360000285121124267